Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

NCT02087943 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic Dermatitis

Interventions

DRUG: Apremilast
DRUG: Apremilast
DRUG: Placebo
DRUG: Placebo

Sponsor

Amgen